We are live on ! Find out more
AGIO icon

Agios Pharmaceuticals
AGIO

167 hedge funds and large institutions have $2.37B invested in Agios Pharmaceuticals in 2017 Q2 according to their latest regulatory filings, with 28 funds opening new positions, 84 increasing their positions, 34 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

147% more repeat investments, than reductions

Existing positions increased: 84 | Existing positions reduced: 34

75% more first-time investments, than exits

New positions opened: 28 | Existing positions closed: 16

7% more funds holding

Funds holding: 156 → 167 (+11)

1% less capital invested

Capital invested by funds: $2.39B → $2.37B (-$19.4M)

1.34% less ownership

Funds ownership: 97.02% → 95.68% (-1.3%)

38% less call options, than puts

Call options by funds: $11.1M | Put options by funds: $17.9M

43% less funds holding in top 10

Funds holding in top 10: 7 → 4 (-3)

Holders
167
Holders Change
+11
Holders Change %
+7.05%
% of All Funds
4.16%
Holding in Top 10
4
Holding in Top 10 Change
-3
Holding in Top 10 Change %
-42.86%
% of All Funds
0.1%
New
28
Increased
84
Reduced
34
Closed
16
Calls
$11.1M
Puts
$17.9M
Net Calls
-$6.77M
Net Calls Change
-$3.2M

Top Buyers

1
Fidelity Investments
Fidelity Investments
Massachusetts
+$45.8M
2
Wellington Management Group
Wellington Management Group
Massachusetts
+$43.7M
3
Invesco
Invesco
Georgia
+$34.3M
4
Vanguard Group
Vanguard Group
Pennsylvania
+$31.6M
5
BlackRock
BlackRock
New York
+$26M

Top Sellers

1
FP
Flagship Pioneering
Massachusetts
-$56.4M
2
RG
Redmile Group
California
-$11.3M
3
CGT
Capital Guardian Trust
California
-$7.88M
4
GTC
Ghost Tree Capital
New York
-$7.3M
5
Capital Fund Management (CFM)
Capital Fund Management (CFM)
France
-$5.15M
Name Holding Trade Value Shares
Change 		Change in
Stake
Lord, Abbett & Co
26
Lord, Abbett & Co
New Jersey
$13.7M +$6.13M +119,836 +81%
Deutsche Bank
27
Deutsche Bank
Germany
$13.4M +$4.85M +94,822 +57%
CC
28
Casdin Capital
New York
$13.1M +$895K +17,500 +7%
Northern Trust
29
Northern Trust
Illinois
$12M +$2.84M +55,560 +31%
BNP Paribas Asset Management
30
BNP Paribas Asset Management
France
$10.6M +$2.33M +45,671 +29%
Point72 Asset Management
31
Point72 Asset Management
Connecticut
$10.4M +$7.18M +140,500 +225%
PP
32
PDT Partners
New York
$9.56M +$9.5M +185,900 New
Bank of New York Mellon
33
Bank of New York Mellon
New York
$8.73M +$2.2M +43,058 +34%
Jennison Associates
34
Jennison Associates
New York
$8.56M -$171K -3,344 -2%
Axa
35
Axa
France
$8.44M +$5.1M +99,683 +155%
Citadel Advisors
36
Citadel Advisors
Florida
$7.99M +$7.94M +155,353 New
CIS
37
Capital International Sarl
California
$7.93M +$51.1K +1,000 +0.7%
CS
38
Credit Suisse
Switzerland
$7.29M -$1.57M -30,735 -18%
OM
39
Opaleye Management
Massachusetts
$6.69M – – –
BBA
40
Baker Bros. Advisors
New York
$6.62M – – –
ACH
41
ArrowMark Colorado Holdings
Colorado
$6.49M – – –
SAM
42
Sectoral Asset Management
Quebec, Canada
$6.36M +$3.7M +72,399 +141%
CBT
43
Capital Bank & Trust
California
$6.31M +$6.27M +122,605 New
HRCM
44
Hood River Capital Management
Florida
$6.12M +$134K +2,626 +2%
TCIM
45
TIAA CREF Investment Management
New York
$6.03M +$1.43M +28,030 +31%
CGL
46
Clarius Group LLC
Washington
$5.62M – – –
Handelsbanken Fonder
47
Handelsbanken Fonder
Sweden
$5.27M +$4.22M +82,500 +413%
New York State Common Retirement Fund
48
New York State Common Retirement Fund
New York
$5.02M +$1.25M +24,399 +33%
Charles Schwab
49
Charles Schwab
California
$4.98M +$692K +13,539 +16%
Wells Fargo
50
Wells Fargo
California
$4.92M +$2.84M +55,463 +138%
1
2
3 4 5

AGIO Hedge Fund Activity: Q2 2017 in Review

167 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Agios Pharmaceuticals (AGIO) for Q2 2017, worth a combined $2.37B — down 0.81% from $2.39B a quarter earlier.

Buyers outnumbered sellers: 28 funds opened new AGIO positions and 16 closed out — a net gain of 12 holders — while 84 added to existing stakes and 34 trimmed.

The largest buyer was Fidelity Investments, adding an estimated $45.8M. The largest seller was Flagship Pioneering, exiting entirely with an estimated $56.4M sold.

  • 167 institutional investors held Agios Pharmaceuticals (AGIO) as of Q2 2017, up from 156 in Q1 2017.
  • Funds reported $2.37B of Agios Pharmaceuticals stock for Q2 2017, down 0.81% quarter-over-quarter.
  • 28 funds opened new Agios Pharmaceuticals positions in Q2 2017 and 16 closed out, a net change of +12 holders.
  • The largest Agios Pharmaceuticals buyer in Q2 2017 was Fidelity Investments, an estimated $45.8M added.
  • The largest Agios Pharmaceuticals seller in Q2 2017 was Flagship Pioneering, an estimated $56.4M sold.

Based on aggregated 13F filings for Q2 2017.